FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311871295> ?p ?o ?g. }

• W4311871295 abstract "Netherton syndrome is a rare, life-threatening autosomal recessive genetic disorder with no effective treatment yet. Skin barrier dysfunction caused by SPINK5 gene mutations is a hallmark of the disease. Antigen penetration through the defective skin and nonspecific inflammation provide a pro-T helper 2 (Th2) immune microenvironment in the disease. Therefore, Th2 cytokines are considered to be candidate therapeutic targets.To evaluate the clinical responses of patients with Netherton syndrome to dupilumab, an IL-4Rα antagonist, and identify changes in the Th1/2/17 pathway activity, skin barrier defect protein LEKTI expression after treatment.Four children with severe Netherton syndrome (aged 2 y to 4 y and 6 m) who were treated with dupilumab from January to June 2022 were evaluated at baseline, and at 4, 8, 12, 16, and 20 weeks after the start of dupilumab administration. Treatment response was assessed using the Eczema Area and Severity Index (EASI), the Numerical Rating Scale (NRS), the Dermatology Life Quality Index (CDLQI), and the Dermatitis Family Impact-questionnaire (DFI). Blood eosinophil counts, serum IgE levels and inflammatory cytokines were measured. The immunotyping of Th1/2/17 cells was performed by flow cytometry and cytokine expressions in T cell subsets were analyzed by single-cell RNA sequencing. In addition, expression of the LEKTI in skin lesions was evaluated by immunohistochemical analysis.All four patients experienced clinical improvement, with significantly reduced EASI scores (by 75.0-83.9%) and NRS (by 87.5-90.0%) from baseline to 20 weeks of treatment. Improved quality of life scores were also seen for all patients, as measured by CDLQI and DFI. Serum IgE levels also fell by 75.6-86.9%. The serum Th2 cytokines IL-4, IL-5 and IL-13 were found at low level, with no significant changes during the treatment. However, Th2 cytokines expressed by T cells, especially IL-4, decreased at single-cell level after treatment (P = 0.029). The baseline percentage of Th2 cells (among total CD3+CD4+ T cells) was significantly higher in patients than that in healthy controls (HC) (P < 0.0001); this percentage fell from 8.25% ± 0.75% to 4.02% ± 0.62% after 20 weeks dupilumab treatment. There was no noticeable change in LEKTI protein expression in skin lesions pre- and post-treatment. Two patients reported mild ocular adverse effects, but there were no severe adverse events.Dupilumab may be an effective and safe treatment option in a subset of pediatric patients with Netherton syndrome, especially in improving itch and the quality of life. These effects were achieved in part by suppression of the Th2-mediated inflammation." @default.
• W4311871295 created "2023-01-01" @default.
• W4311871295 creator A5052084683 @default.
• W4311871295 creator A5053725057 @default.
• W4311871295 creator A5058601195 @default.
• W4311871295 creator A5074249401 @default.
• W4311871295 creator A5075248184 @default.
• W4311871295 creator A5077906192 @default.
• W4311871295 creator A5079749941 @default.
• W4311871295 creator A5085446981 @default.
• W4311871295 creator A5085699934 @default.
• W4311871295 date "2022-12-08" @default.
• W4311871295 modified "2023-10-17" @default.
• W4311871295 title "Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation" @default.
• W4311871295 cites W1990263353 @default.
• W4311871295 cites W2031095563 @default.
• W4311871295 cites W2040736784 @default.
• W4311871295 cites W2066572887 @default.
• W4311871295 cites W2200308911 @default.
• W4311871295 cites W2955867719 @default.
• W4311871295 cites W3004283122 @default.
• W4311871295 cites W3028491484 @default.
• W4311871295 cites W3030687156 @default.
• W4311871295 cites W3031280208 @default.
• W4311871295 cites W3065759430 @default.
• W4311871295 cites W3087163206 @default.
• W4311871295 cites W3115059068 @default.
• W4311871295 cites W3137798254 @default.
• W4311871295 cites W3201641381 @default.
• W4311871295 cites W3215465524 @default.
• W4311871295 cites W4213452913 @default.
• W4311871295 cites W4214871602 @default.
• W4311871295 cites W4220805953 @default.
• W4311871295 cites W4220959337 @default.
• W4311871295 cites W4295895500 @default.
• W4311871295 doi "https://doi.org/10.3389/fimmu.2022.1054422" @default.
• W4311871295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36569942" @default.
• W4311871295 hasPublicationYear "2022" @default.
• W4311871295 type Work @default.
• W4311871295 citedByCount "2" @default.
• W4311871295 countsByYear W43118712952023 @default.
• W4311871295 crossrefType "journal-article" @default.
• W4311871295 hasAuthorship W4311871295A5052084683 @default.
• W4311871295 hasAuthorship W4311871295A5053725057 @default.
• W4311871295 hasAuthorship W4311871295A5058601195 @default.
• W4311871295 hasAuthorship W4311871295A5074249401 @default.
• W4311871295 hasAuthorship W4311871295A5075248184 @default.
• W4311871295 hasAuthorship W4311871295A5077906192 @default.
• W4311871295 hasAuthorship W4311871295A5079749941 @default.
• W4311871295 hasAuthorship W4311871295A5085446981 @default.
• W4311871295 hasAuthorship W4311871295A5085699934 @default.
• W4311871295 hasBestOaLocation W43118712951 @default.
• W4311871295 hasConcept C126322002 @default.
• W4311871295 hasConcept C203014093 @default.
• W4311871295 hasConcept C2776042228 @default.
• W4311871295 hasConcept C2776173921 @default.
• W4311871295 hasConcept C2777037409 @default.
• W4311871295 hasConcept C2778329239 @default.
• W4311871295 hasConcept C2779134260 @default.
• W4311871295 hasConcept C2779824493 @default.
• W4311871295 hasConcept C2780194698 @default.
• W4311871295 hasConcept C2780699399 @default.
• W4311871295 hasConcept C71924100 @default.
• W4311871295 hasConcept C8891405 @default.
• W4311871295 hasConceptScore W4311871295C126322002 @default.
• W4311871295 hasConceptScore W4311871295C203014093 @default.
• W4311871295 hasConceptScore W4311871295C2776042228 @default.
• W4311871295 hasConceptScore W4311871295C2776173921 @default.
• W4311871295 hasConceptScore W4311871295C2777037409 @default.
• W4311871295 hasConceptScore W4311871295C2778329239 @default.
• W4311871295 hasConceptScore W4311871295C2779134260 @default.
• W4311871295 hasConceptScore W4311871295C2779824493 @default.
• W4311871295 hasConceptScore W4311871295C2780194698 @default.
• W4311871295 hasConceptScore W4311871295C2780699399 @default.
• W4311871295 hasConceptScore W4311871295C71924100 @default.
• W4311871295 hasConceptScore W4311871295C8891405 @default.
• W4311871295 hasFunder F4320321001 @default.
• W4311871295 hasLocation W43118712951 @default.
• W4311871295 hasLocation W43118712952 @default.
• W4311871295 hasLocation W43118712953 @default.
• W4311871295 hasOpenAccess W4311871295 @default.
• W4311871295 hasPrimaryLocation W43118712951 @default.
• W4311871295 hasRelatedWork W2789024274 @default.
• W4311871295 hasRelatedWork W2916274906 @default.
• W4311871295 hasRelatedWork W2995377367 @default.
• W4311871295 hasRelatedWork W3185091247 @default.
• W4311871295 hasRelatedWork W3193824504 @default.
• W4311871295 hasRelatedWork W3204561650 @default.
• W4311871295 hasRelatedWork W4221014321 @default.
• W4311871295 hasRelatedWork W4237621822 @default.
• W4311871295 hasRelatedWork W4287189041 @default.
• W4311871295 hasRelatedWork W3024049657 @default.
• W4311871295 hasVolume "13" @default.
• W4311871295 isParatext "false" @default.
• W4311871295 isRetracted "false" @default.
• W4311871295 workType "article" @default.